BBZA.F BB Biotech AG
- Market cap
- EUR 3.24B
- P/E
- -
- P/B
- 0.92x
- ROE
- 24.7%
- Dividend yield
- 5.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BBZA.F undervalued?
Graham numberThe Graham number of BB Biotech AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BB Biotech AG fundamental analysis
No fundamental analysis for BB Biotech AG yet.
BB Biotech AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Full company profileBB Biotech AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BB Biotech AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 693M | -466M | 685M | 699M | -396M | -351M | -200M | 82.3M | 587M | 840M |
| Net Income | 688M | -471M | 677M | 691M | -405M | -358M | -207M | 75.9M | 578M | 806M |
| EPS | 12 | -8.51 | 12 | 12 | -7.32 | -6.52 | -3.77 | 1.39 | 10 | 15 |
| Balance Sheet | ||||||||||
| Total Assets | 3.64B | 3.09B | 3.55B | 3.96B | 3.64B | 3.05B | 2.64B | 2.41B | 2.79B | 3.30B |
| Total Liabilities | 99.1M | 202M | 162M | 75.6M | 361M | 367M | 314M | 121M | 6.97M | 38.1M |
| Shareholders' Equity | 3.54B | 2.88B | 3.39B | 3.89B | 3.28B | 2.69B | 2.32B | 2.29B | 2.78B | 3.26B |
| Cash & Short-term Investments | 10.7M | 22.1M | 30.7M | 6.82M | 2.84M | 1.95M | 501K | 458K | 98.2M | 168M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 263M | 108M | 215M | 262M | -94.8M | 231M | - | - | - | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 263M | 108M | 215M | 262M | -94.8M | 231M | 159M | 305M | 309M | 240M |
| Ratios | ||||||||||
| ROE | 19.4% | -16.3% | 20.0% | 17.8% | -12.3% | -13.3% | -8.9% | 3.3% | 20.8% | 24.7% |
| ROA | 18.9% | -15.3% | 19.1% | 17.4% | -11.1% | -11.7% | -7.8% | 3.2% | 20.8% | 24.5% |
| Net Profit Margin | 99.2% | - | 98.9% | 98.8% | - | - | - | 92.2% | 98.5% | 95.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BB Biotech AG dividends
- Dividend yield
- 5.66%
- Forward dividend
- 1.89 EUR
- Payout ratio
- 17.0%
- Ex-dividend date
- Mar 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CHF 98.5M | 1.79 | 17.0% |
| 2024 | CHF 110M | 2.00 | 144.5% |
| 2023 | CHF 156M | 2.85 | - |
| 2022 | CHF 212M | 3.87 | - |
| 2021 | CHF 199M | 3.61 | - |
| 2020 | CHF 188M | 3.40 | 27.3% |
| 2019 | CHF 169M | 3.05 | 24.9% |
| 2018 | CHF 183M | 3.30 | - |
| 2017 | CHF 152M | 2.74 | 22.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Mar 29, 2016.
Who owns BB Biotech AG
- Insiders 0.08%
- Institutions 20.71%
- Public & others 79.22%
- Shares outstanding 55.1M
BB Biotech AG company profile
- Company name
- BB Biotech AG
- Ticker
- BBZA.F
- ISIN
- CH0038389992
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- Seestrasse 16, Küsnacht, Switzerland, CH-8700
- Phone
- 41 44 2676700
- Website
- bbbiotech.ch/en/bb-biotech
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
BB Biotech AG management
1- Dr. Daniel Koller Ph.D.Head of Biotech, Portfolio Manager and Member of Executive Board · born 1970